Ameriprise Financial Inc. Acquires 29,034 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Ameriprise Financial Inc. lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 46.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,670 shares of the company’s stock after acquiring an additional 29,034 shares during the period. Ameriprise Financial Inc.’s holdings in Recursion Pharmaceuticals were worth $620,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after acquiring an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after acquiring an additional 1,875 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 28.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock valued at $69,000 after acquiring an additional 2,235 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after purchasing an additional 2,387 shares during the last quarter. Finally, Xponance Inc. lifted its stake in Recursion Pharmaceuticals by 22.2% in the fourth quarter. Xponance Inc. now owns 19,163 shares of the company’s stock worth $130,000 after purchasing an additional 3,480 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

RXRX has been the subject of several analyst reports. Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.60.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $4.39 on Wednesday. The firm has a market cap of $1.78 billion, a PE ratio of -2.87 and a beta of 0.99. The firm’s 50 day simple moving average is $4.84 and its 200-day simple moving average is $6.37. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to analysts’ expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business posted ($0.39) earnings per share. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.